Clinical Trials Sponsored by Merrimack Pharmaceuticals
Total 19729 results
-
Regeneron PharmaceuticalsTerminatedHypertriglyceridemiaUnited States, Germany, Netherlands, Canada
-
Ferring PharmaceuticalsCompletedMild-to-moderate Ulcerative ColitisPoland, Hungary, Italy, Czechia, Netherlands, Slovakia
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
-
Marinus PharmaceuticalsActive, not recruitingTuberous Sclerosis ComplexUnited States, Spain, United Kingdom, Israel, Italy, Germany, France, Canada
-
Alnylam PharmaceuticalsActive, not recruitingHypertensionUnited States, Canada, Latvia, Poland, United Kingdom, Germany, Lithuania, Estonia, Puerto Rico
-
X4 PharmaceuticalsActive, not recruiting
-
Arrowhead PharmaceuticalsActive, not recruitingHomozygous Familial HypercholesterolemiaAustralia, Canada, United States, South Africa
-
Santhera PharmaceuticalsSanthera PharmaceuticalsActive, not recruitingDuchenne Muscular DystrophyCanada
-
ASLAN PharmaceuticalsCompletedAtopic DermatitisUnited States, Australia, Singapore, India, Canada, New Zealand, Dominican Republic, Poland
-
Alnylam PharmaceuticalsCompletedAmyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid PolyneuropathiesUnited States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Germany, France, Brazil, Turkey, Korea, Republic of, Taiwan, United Kingdom
-
Sparrow PharmaceuticalsCompletedA Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62Obesity | Type 2 Diabetes Mellitus in Obese | Type2DiabetesUnited States
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisPortugal, Spain, Sweden, Brazil, United States, France, Germany
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Vanda PharmaceuticalsCompletedBipolar I DisorderUnited States, Bulgaria, Poland
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
Ferring PharmaceuticalsCompletedControlled Ovarian StimulationDenmark, Norway, Sweden, Switzerland
-
Azurity PharmaceuticalsCompletedAbuse PotentialUnited States
-
Intercept PharmaceuticalsActive, not recruitingPrimary Biliary CholangitisUnited States
-
Vanda PharmaceuticalsActive, not recruitingNon 24 Hour Sleep Wake DisorderFrance
-
Regeneron PharmaceuticalsActive, not recruitingHealthy VolunteersBelgium
-
Regeneron PharmaceuticalsActive, not recruiting
-
Alnylam PharmaceuticalsTerminated
-
Vanda PharmaceuticalsCompletedAutism Spectrum Disorder | Smith-Magenis Syndrome | Non-24 Hour Sleep-Wake Disorder | Circadian Rhythm Sleep DisordersUnited States
-
BioCryst PharmaceuticalsActive, not recruitingHereditary Angioedema | PediatricSpain, Austria, Canada, France, Germany, Israel, Italy, Poland, Romania, United Kingdom
-
CStone PharmaceuticalsCompletedRelapsed Small Cell Lung CancerChina
-
Constellation PharmaceuticalsCompletedSolid Tumor | Advanced Malignancies | Hematological MalignancySpain, United States, Georgia
-
Longboard PharmaceuticalsAvailableDravet Syndrome | Lennox Gastaut Syndrome | Developmental and Epileptic EncephalopathiesUnited States
-
BioCryst PharmaceuticalsTerminatedBCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)Paroxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Hungary, France, Italy, Spain
-
Alnylam PharmaceuticalsNo longer availableTransthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With CardiomyopathyUnited States
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
-
Alnylam PharmaceuticalsApproved for marketingPrimary HyperoxaluriaBelgium
-
Botanix PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedInfertility, FemaleUnited States
-
Endo PharmaceuticalsCompletedProstate Cancer | Adenocarcinoma of the Prostate
-
Endo PharmaceuticalsCompleted
-
Endo PharmaceuticalsCompletedCarpal Tunnel Syndrome | Complex Regional Pain Syndrome | Peripheral Neuropathy | Diabetic Neuropathy | Postherpetic Neuralgia | HIV Neuropathy | Idiopathic Sensory NeuropathyUnited States
-
Ferring PharmaceuticalsCompletedProstate CancerDenmark, Sweden, Finland, Hungary, Norway, Romania, Russian Federation
-
Regeneron PharmaceuticalsCompleted
-
Response PharmaceuticalsCompletedDrug-induced Weight GainUnited States
-
Lexicon PharmaceuticalsCompletedPostherpetic NeuralgiaUnited States, Czechia, Poland
-
Response PharmaceuticalsCompletedType 2 Diabetes MellitusUnited States
-
Ferring PharmaceuticalsCompletedCrohn's DiseaseUnited States, Netherlands, Israel, Germany
-
Santhera PharmaceuticalsAvailableDuchenne Muscular DystrophyUnited States, Canada, Israel
-
Arrowhead PharmaceuticalsActive, not recruitingDyslipidemiasUnited States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
-
ERX PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsAvailableParoxysmal Nocturnal Hemoglobinuria (PNH) | CD55-deficient Protein-losing Enteropathy (PLE) | CD59 Deficiency
-
Intercept PharmaceuticalsTerminatedNon Alcoholic Steatohepatitis (NASH)United States, Finland, France, Spain, United Kingdom, Israel, Austria, Italy, Denmark, Germany, Belgium, Switzerland, Puerto Rico, Poland, Australia, Sweden, Serbia, New Zealand, Canada, Hungary, Portugal
-
eXIthera PharmaceuticalsWithdrawnCovid19 | ThrombopeniaUnited States